Results 11 to 20 of about 721 (146)

Oral varespladib for the treatment of snakebite envenoming in India and the USA (BRAVO): a phase II randomised clinical trial [PDF]

BMJ Global Health
Introduction Snakebite envenoming (SBE) results in over 500 000 deaths or disabling injuries annually. Varespladib methyl, an oral inhibitor of secretory phospholipase A2, is a nearly ubiquitous component of snake venoms. We conducted a phase II clinical
Chanaveerappa Bammigatti, Timothy F Platts-Mills, Ashish Bhalla, Harish Kumar, Matthew R Lewin, Surendra Kumar, Charles J Gerardo, Rebecca W Carter, Farshad M Shirazi, Suneetha D Kotehal, Peter D Akpunonu, Richard B Schwartz, Neeraj Manikath, Partha P Mukherjee, Thomas C Arnold, Brian J Wolk, Sophia S Sheikh, Dawn R Sollee, David J Vearrier, Samuel J Francis, Adiel Aizenberg, Madhu K Ravikumar, Sujoy Sarkar, Taylor Haston, Andrew Micciche, Suraj C Oomman, Jeffery L Owen, Brandi A Ritter, Stephen P Samuel   +28 more
doaj   +5 more sources

Ex vivo effect of varespladib on secretory phospholipase A2 alveolar activity in infants with ARDS. [PDF]

PLoS ONE, 2012
Secretory phospholipase A2 (sPLA2) plays a pivotal role in acute respiratory distress syndrome (ARDS). This enzyme seems an interesting target to reduce surfactant catabolism and lung tissue inflammation.
Daniele De Luca, Angelo Minucci, Marco Piastra, Paola E Cogo, Francesca Vendittelli, Laura Marzano, Leonarda Gentile, Bruno Giardina, Giorgio Conti, Ettore D Capoluongo   +9 more
doaj   +8 more sources

Varespladib Inhibits the Phospholipase A₂ and Coagulopathic Activities of Venom Components from Hemotoxic Snakes [PDF]

Biomedicines, 2020
Phospholipase A2 (PLA2) enzymes are important toxins found in many snake venoms, and they can exhibit a variety of toxic activities including causing hemolysis and/or anticoagulation.
Chunfang Xie, Laura-Oana Albulescu, Kristina B. M. Still, Julien Slagboom, Yumei Zhao, Zhengjin Jiang, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Jeroen Kool   +9 more
doaj   +7 more sources

In Vitro Efficacy of Antivenom and Varespladib in Neutralising Chinese Russell’s Viper (Daboia siamensis) Venom Toxicity

Toxins, 2023
The venom of the Russell’s viper (Daboia siamensis) contains neurotoxic and myotoxic phospholipase A2 toxins which can cause irreversible damage to motor nerve terminals.
Mimi Lay, Qing Liang, Geoffrey K. Isbister, Wayne C. Hodgson   +3 more
doaj   +4 more sources

Oral and IV Varespladib Rescue Experiments in Juvenile Pigs with Weakness Induced by Australian and Papuan Oxyuranus scutellatus Venoms

Toxins, 2023
Antivenom is currently the standard-of-care treatment for snakebite envenoming, but its efficacy is limited by treatment delays, availability, and in many cases, species specificity.
Lyndi L. Gilliam, John Gilliam, Stephen P. Samuel, Rebecca W. Carter, Jerry Ritchey, Tommaso Bulfone, José María Gutiérrez, David J. Williams, Daniela M. Durkin, Sally I. Stephens, Matthew R. Lewin   +10 more
doaj   +4 more sources

The BRAVO Clinical Study Protocol: Oral Varespladib for Inhibition of Secretory Phospholipase A2 in the Treatment of Snakebite Envenoming

Toxins, 2022
Introduction: Snakebite is an urgent, unmet global medical need causing significant morbidity and mortality worldwide. Varespladib is a potent inhibitor of venom secretory phospholipase A2 (sPLA2) that can be administered orally via its prodrug ...
Rebecca W. Carter, Charles J. Gerardo, Stephen P. Samuel, Surendra Kumar, Suneetha D. Kotehal, Partha P. Mukherjee, Farshad M. Shirazi, Peter D. Akpunonu, Chanaveerappa Bammigatti, Ashish Bhalla, Neeraj Manikath, Timothy F. Platts-Mills, Matthew R. Lewin   +12 more
doaj   +4 more sources

Inhibitory Effects of Varespladib, CP471474, and Their Potential Synergistic Activity on Bothrops asper and Crotalus durissus cumanensis Venoms

Molecules, 2022
Snakebite is a neglected tropical disease that causes extensive mortality and morbidity in rural communities. Antivenim sera are the currently approved therapy for snake bites; however, they have some therapeutic limitations that have been extensively ...
Sara Quiroz, Isabel C. Henao Castañeda, Johan Granados, Arley Camilo Patiño, Lina María Preciado, Jaime Andrés Pereañez   +5 more
doaj   +5 more sources

PLA₂ Inhibitor Varespladib as an Alternative to the Antivenom Treatment for Bites from Nikolsky’s Viper Vipera berus nikolskii [PDF]

Toxins, 2020
Although envenoming by a small East European species of viper is rarely severe, and only exceptionally fatal, lack of specific antivenom stocks in a few areas within this region and possible severe side effects of antivenom application leave most bites ...
Oleksandr Zinenko, Igor Tovstukha, Yevgen Korniyenko   +2 more
doaj   +4 more sources

Endogenous “Time Bomb” – Mislocalized Phospholipase A2 as a Critical Mediator of Ultra‐Rapid Mortality in Sepsis and Acute Lung Injury [PDF]

Advanced Science
This study reveals that phospholipase A2 (PLA2), normally stable and nontoxic, can be activated specifically within the alveolar environment to induce rapid, “electric shock‐like” lethality, akin to chemical toxins, while also exhibiting extreme toxicity
Jianyu Wang, Zhongxing Xu, Lin Wang, Xin Sui, Yuan Luo, Xiuli Zhao, Jun Yang, Yongan Wang   +7 more
doaj   +3 more sources

Anticoagulant Activity of Naja nigricollis Venom Is Mediated by Phospholipase A2 Toxins and Inhibited by Varespladib [PDF]

Toxins, 2021
Bites from elapid snakes typically result in neurotoxic symptoms in snakebite victims. Neurotoxins are, therefore, often the focus of research relating to understanding the pathogenesis of elapid bites.
Taline D. Kazandjian, Arif Arrahman, Kristina B. M. Still, Govert W. Somsen, Freek J. Vonk, Nicholas R. Casewell, Mark C. Wilkinson, Jeroen Kool   +7 more
doaj   +5 more sources